Bolt Biotherapeutics, Inc. (BOLT)
NASDAQ: BOLT · Real-Time Price · USD
0.567
-0.003 (-0.49%)
Nov 21, 2024, 4:00 PM EST - Market closed
Bolt Biotherapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
Cash & Equivalents | 9.37 | 10.81 | 9.24 | 27.38 | 5.54 | 34.83 | Upgrade
|
Short-Term Investments | 44.43 | 91.38 | 159.64 | 158.84 | 17.3 | - | Upgrade
|
Cash & Short-Term Investments | 53.8 | 102.19 | 168.89 | 186.22 | 22.84 | 34.83 | Upgrade
|
Cash Growth | -55.06% | -39.49% | -9.31% | 715.39% | -34.42% | 155.43% | Upgrade
|
Other Receivables | - | 1.3 | - | - | - | 0.3 | Upgrade
|
Receivables | - | 1.3 | - | - | - | 0.3 | Upgrade
|
Prepaid Expenses | 2.56 | 2.04 | 3.86 | 2.94 | 2.52 | 0.77 | Upgrade
|
Other Current Assets | - | 0.18 | - | - | - | - | Upgrade
|
Total Current Assets | 57.15 | 105.71 | 172.75 | 189.16 | 25.36 | 35.9 | Upgrade
|
Property, Plant & Equipment | 20.32 | 24.08 | 28.53 | 30.6 | 16.35 | 11.52 | Upgrade
|
Long-Term Investments | 30.6 | 26.41 | 23.94 | 85.35 | - | - | Upgrade
|
Long-Term Deferred Charges | - | 0.37 | - | - | 2.36 | - | Upgrade
|
Other Long-Term Assets | 1.27 | 3.22 | 2.59 | 2.61 | 2.47 | 1.03 | Upgrade
|
Total Assets | 109.33 | 159.78 | 227.81 | 307.72 | 46.54 | 48.45 | Upgrade
|
Accounts Payable | 1.48 | 2.99 | 3.59 | 3.57 | 1.6 | 2.1 | Upgrade
|
Accrued Expenses | 11.81 | 12.49 | 15.14 | 12.38 | 6.66 | 2.87 | Upgrade
|
Current Portion of Leases | 2.82 | 2.78 | 2.39 | 2.5 | 1.5 | 3.1 | Upgrade
|
Current Unearned Revenue | 1.97 | 2.2 | 1.99 | 2.87 | 1.5 | 0.6 | Upgrade
|
Total Current Liabilities | 18.08 | 20.46 | 23.12 | 21.33 | 11.26 | 8.66 | Upgrade
|
Long-Term Leases | 15.35 | 17.44 | 20.22 | 21.85 | 9.38 | 7.09 | Upgrade
|
Long-Term Unearned Revenue | 3.87 | 9.11 | 12.92 | 14.21 | - | 0.97 | Upgrade
|
Other Long-Term Liabilities | - | 0.04 | 0.04 | 0.21 | 0.33 | 0.07 | Upgrade
|
Total Liabilities | 37.3 | 47.04 | 56.3 | 57.6 | 20.97 | 16.79 | Upgrade
|
Common Stock | 0 | 0 | - | - | - | - | Upgrade
|
Additional Paid-In Capital | 483.29 | 476.99 | 467.51 | 457.43 | 3.45 | 1.83 | Upgrade
|
Retained Earnings | -411.47 | -364.29 | -295.09 | -206.99 | -108.4 | -47.67 | Upgrade
|
Comprehensive Income & Other | 0.21 | 0.04 | -0.92 | -0.32 | - | - | Upgrade
|
Total Common Equity | 72.03 | 112.74 | 171.51 | 250.12 | -104.95 | -45.85 | Upgrade
|
Shareholders' Equity | 72.03 | 112.74 | 171.51 | 250.12 | 25.57 | 31.66 | Upgrade
|
Total Liabilities & Equity | 109.33 | 159.78 | 227.81 | 307.72 | 46.54 | 48.45 | Upgrade
|
Total Debt | 18.18 | 20.22 | 22.61 | 24.36 | 10.88 | 10.19 | Upgrade
|
Net Cash (Debt) | 35.62 | 81.97 | 146.28 | 161.86 | 11.96 | 24.64 | Upgrade
|
Net Cash Growth | -63.97% | -43.96% | -9.63% | 1253.26% | -51.46% | 81.26% | Upgrade
|
Net Cash Per Share | 0.93 | 2.17 | 3.92 | 4.88 | 5.69 | 12.36 | Upgrade
|
Filing Date Shares Outstanding | 38.27 | 38.13 | 37.81 | 37.47 | 36.33 | 1.92 | Upgrade
|
Total Common Shares Outstanding | 38.27 | 38.11 | 37.8 | 37.4 | 2.13 | 1.92 | Upgrade
|
Working Capital | 39.06 | 85.25 | 149.63 | 167.83 | 14.1 | 27.24 | Upgrade
|
Book Value Per Share | 1.88 | 2.96 | 4.54 | 6.69 | -49.27 | -23.86 | Upgrade
|
Tangible Book Value | 72.03 | 112.74 | 171.51 | 250.12 | -104.95 | -45.85 | Upgrade
|
Tangible Book Value Per Share | 1.88 | 2.96 | 4.54 | 6.69 | -49.27 | -23.86 | Upgrade
|
Machinery | - | 10.42 | 10.1 | 8.26 | 5.32 | 2.03 | Upgrade
|
Leasehold Improvements | - | 0.29 | 0.27 | 0.15 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.